Annual Financial Report

/**/ ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .bs{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.bs{}p.co{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:-16.7pt;margin-bottom: 10.0pt;margin-left:-9.0pt}span.cm{font-size:10.0pt;line-height:115%; font-family:"Century Gothic Pro Grk","sans-serif"}p.cp{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 10.0pt; margin-left: -9.0pt; margin-right: -16.7pt; margin-top: 0cm; text-align: center}span.ck{font-size:10.0pt;line-height:115%;font-family:"Century Gothic Pro Grk","sans-serif"}p.cq{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom: 10.0pt; margin-left: -9.0pt; margin-right: -16.7pt; margin-top: 0cm; text-align: center}p.cr{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 11.0pt; text-align: center}span.ch{font-size:10.0pt;font-family:"Century Gothic Pro Grk","sans-serif"; color:black}p.cs{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:11.0pt;text-align:justify;line-height: normal} span.cf{font-size:10.0pt; font-family:"Century Gothic Pro Grk","sans-serif";color:black}p.ct{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:11.0pt;line-height:normal}table.cu{width:20.0cm}tr.bz{height:19.85pt}td.cb{width:354.4pt;padding:0cm 0cm 0cm 0cm; height:19.85pt}p.cv{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 11.0pt; margin-left: 0cm; margin-right: -66.0pt; margin-top: 0cm}td.ca{width:212.6pt;padding:0cm 0cm 0cm 0cm; height:19.85pt}tr.bw{height:32.8pt}td.by{width:354.4pt;padding:0cm 0cm 0cm 0cm; height:32.8pt}td.bx{width:212.6pt;padding:0cm 0cm 0cm 0cm; height:32.8pt} p.cw{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 11.0pt; text-align: justify}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";}span.bt{font-size:10.0pt;line-height:115%;font-family: "Century Gothic Pro Grk","sans-serif";color:black} /**/
RNS Number : 1836O
30 September 2019

30 September 2019          


("Abcam" or "the Company")

Publication of 2019 Annual Report and Accounts

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that its Annual Report and Accounts for the year ended 30 June 2019 will be published today on the Company's investor relations website, www.abcamplc.com

It will also be posted today, together with the Notice of Annual General Meeting, to those shareholders that have elected to receive paper communications.  Shareholders that have not elected to receive paper communications will be notified of the availability of these documents on the Company's investor relations website, www.abcamplc.com.

For further information please contact:

Abcam plc

+ 44 (0) 1223 696 000

Marc Perkins, Company Secretary

James Staveley, Vice President Investor Relations


About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Group offers highly validated antibodies and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Some two-thirds of the world's 750,000 life science researchers use Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Group continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 140 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

Please visit www.abcam.com or www.abcamplc.com to find out more.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Abcam

Price: 1271

Market: AIM
Market Cap: £2.62 billion

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Result of AGM

13 hours, 23 minutes ago

Director/PDMR Shareholding

1 week, 1 day ago

Total Voting Rights

1 week, 6 days ago

Total Voting Rights

on 1/10/19